Aug 8 (Reuters)-
OncoTherapy Science Inc
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2025 Jun 30, 2024 Mar 31, 2026
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 201 mln 100 mln
(+100.1 pct) (-32.0 pct)
Operating loss 303 mln loss 290 mln
Recurring loss 313 mln loss 302 mln
Net loss 314 mln loss 302 mln
EPS loss 1.13 yen loss 1.30 yen
Ann Div NIL NIL
-Q2 div
-Q4 div NIL NIL
NOTE - OncoTherapy Science Inc.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4564.T